An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
Study Identifier:
C10-003
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Eculizumab
Date
Sep 2010 - Jan 2014
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 1 Month - 18 Years
Requirements Information
Sex
Female & Male
Age
1 Month - 18 Years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Eculizumab
Date
Sep 2010 - Jan 2014
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 1 Month - 18 Years years
Requirements Information
Protocol Summary
The primary purpose is to assess the efficacy and safety of eculizumab in pediatric patients with aHUS to control TMA as characterized by thrombocytopenia, hemolysis and renal impairment.
Trial Locations
Location
Status
Location
Atlanta, Georgia, United States, 30322
Status
N/A
Location
Hackensack, New Jersey, United States, 07601
Status
N/A
Location
Corpus Christi, Texas, United States, 78411
Status
N/A
Location
Spokane, Washington, United States, 99204
Status
N/A
Location
North Adelaide, South Australia, Australia, 5006
Status
N/A
Location
Gent, Belgium, 9000
Status
N/A